Top Industry Leaders in the Chiari Malformation Market
Latest Chiari Malformation Companies Updates:
Surgeonet's NeuroGlide® Cervical Decompression System Received FDA approval in October 2023 for minimally invasive decompression surgery in patients with Chiari Type I Malformation. This offers an alternative to traditional, more invasive open surgery.
MDI's VentriFlow™ CSF Diversion System Phase 2 trial results presented in November 2023 showed promising effectiveness in managing syringomyelia associated with Chiari Malformation.
Novel Biomarkers Companies are exploring potential biomarkers for early detection and diagnosis of Chiari Malformation, aiming to improve patient outcomes and reduce unnecessary surgeries.
List of Chiari Malformation Key companies in the market:
- Abbott Laboratories, Inc.
- Becton, Dickinson and Company
- Novartis AG
- Johnson & Johnson
- Pfizer, Inc.
- Sanofi-Aventis
- GlaxoSmithKline